- Report
- January 2025
- 122 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- April 2025
- 200 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- September 2024
- 150 Pages
Global
From €2911EUR$3,250USD£2,481GBP
€4344EUR$4,850USD£3,703GBP
- Report
- September 2024
- 154 Pages
Global
From €2015EUR$2,250USD£1,718GBP
- Report
- May 2025
- 183 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 187 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- May 2025
- 197 Pages
Global
From €3175EUR$3,545USD£2,707GBP
€3528EUR$3,939USD£3,008GBP
- Report
- April 2025
- 144 Pages
Global
From €2686EUR$2,999USD£2,290GBP
- Report
- November 2024
- 100 Pages
Global
From €5329EUR$5,950USD£4,543GBP
- Report
- June 2025
- 503 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 78 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- June 2025
- 89 Pages
Global
From €5240EUR$5,850USD£4,467GBP
- Report
- March 2025
- 175 Pages
Global
From €4022EUR$4,490USD£3,428GBP
- Report
- January 2025
- 182 Pages
Global
From €3426EUR$3,825USD£2,920GBP
€4031EUR$4,500USD£3,436GBP
- Report
- May 2025
- 215 Pages
Global
From €4031EUR$4,500USD£3,436GBP
- Report
- June 2024
- 140 Pages
Middle East, Africa
From €3465EUR$3,869USD£2,954GBP
- Report
- June 2024
- 140 Pages
Latin America
From €3465EUR$3,869USD£2,954GBP
- Report
- June 2024
- 140 Pages
Europe
From €3465EUR$3,869USD£2,954GBP
- Report
- June 2024
- 120 Pages
North America
From €3465EUR$3,869USD£2,954GBP
- Report
- January 2020
- 508 Pages
Global
From €4388EUR$4,899USD£3,741GBP

The Autologous Stem Cell market is a subset of the larger Stem Cell market. Autologous stem cells are those derived from the patient's own body, and are used to treat a variety of conditions, including degenerative diseases, autoimmune diseases, and tissue damage. Autologous stem cells are typically harvested from the patient's bone marrow, adipose tissue, or peripheral blood. The cells are then processed and expanded in the laboratory before being re-injected into the patient.
The Autologous Stem Cell market is growing rapidly, driven by advances in stem cell technology and the increasing availability of treatments. The market is expected to continue to expand as more treatments become available and the technology continues to improve.
Some companies in the Autologous Stem Cell market include Osiris Therapeutics, Inc., Athersys, Inc., Mesoblast Limited, and Pluristem Therapeutics, Inc. Show Less Read more